Novavax, Inc. (NVAX) News

Novavax, Inc. (NVAX): $20.04

1.17 (+6.20%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add NVAX to Watchlist
Sign Up

Industry: Biotech


Ranked

of 393

in industry

Filter NVAX News Items

NVAX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

NVAX News Highlights

  • NVAX's 30 day story count now stands at 23.
  • Over the past 26 days, the trend for NVAX's stories per day has been choppy and unclear. It has oscillated between 1 and 10.
  • SE and MRNA are the most mentioned tickers in articles about NVAX.

Latest NVAX News From Around the Web

Below are the latest news stories about NOVAVAX INC that investors may wish to consider to help them evaluate NVAX as an investment opportunity.

Novavax Downgraded by JPMorgan Chase. Time to Sell?

The Novavax (NASDAQ: NVAX) rollercoaster has been a wild one. The stock soared more than 2,700% in 2020 after the company received $1.6 billion from the U.S. government to develop the COVID-19 vaccine we now know as Nuvaxovid. Unfortunately, Novavax didn't receive authorization to sell its vaccine in the U.S. until this July.

Yahoo | September 25, 2022

Some Novavax, Inc. (NASDAQ:NVAX) Analysts Just Made A Major Cut To Next Year's Estimates

Market forces rained on the parade of Novavax, Inc. ( NASDAQ:NVAX ) shareholders today, when the analysts downgraded...

Yahoo | September 24, 2022

Novavax, Inc. stock performance and analyst projections

Novavax, Inc. stock is trending on the Yahoo Finance Platform. Here is a visualization of $NVAX performance over time, how that performance compares to the wider industry, and analyst projections for the current quarter.Check out the ticker page here.

Yahoo | September 23, 2022

Why Novavax (NVAX) Stock Was Down 13% on Thursday

Novavax (NVAX) sinks to a new record level 52-week low after analysts at JP Morgan cut the 12-month target price on the stock by more than $100.

Yahoo | September 23, 2022

Spero Therapeutics (SPRO) Soars 137% on Exclusive License Agreement

Spero Therapeutics (SPRO) stock is rocketing higher on Thursday after the company signed a licensing agreement with GSK (GSK).

William White on InvestorPlace | September 22, 2022

What Is Going on With Accenture (ACN) Stock Today?

Accenture (ACN) stock is on the move Thursday after releasing a positive earnings report and announcing a new acquisition.

William White on InvestorPlace | September 22, 2022

Why Is Novavax (NVAX) Stock Falling Today?

Novavax still has cash, but it needs to get approval for another vaccine if NVAX stock is to be worth buying again.

Dana Blankenhorn on InvestorPlace | September 22, 2022

Why Novavax Stock Is Plunging This Week

Novavax has some serious short-term challenges but could still have growth opportunities in the future.

Yahoo | September 22, 2022

Here Are Novavax's U.S. Vaccination Numbers — And They're Bleak

Novavax stock is trading at a two-year low amid slowly ramping use of its Covid vaccine, dubbed Nuvaxovid, in the U.S.

Yahoo | September 22, 2022

Novavax's Covid Vaccine May Pinch, But the Charts Really Hurt

Vaccine maker Novavax has sunk to a new low for the move down as fundamental analysts are publishing weaker ratings. President Biden's recent assessment of Covid has not helped, either. Let's check the charts and indicators.

Yahoo | September 22, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4783 seconds.